Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 8;10(24):5749.
doi: 10.3390/jcm10245749.

Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry

Víctor Moreno-Torres  1 , Carlos Tarín  2 , Guillermo Ruiz-Irastorza  3 , Raquel Castejón  1 , Ángela Gutiérrez-Rojas  1 , Ana Royuela  4 , Pedro Durán-Del Campo  1 , Susana Mellor-Pita  1 , Pablo Tutor  1 , Silvia Rosado  1 , Enrique Sánchez  1 , María Martínez-Urbistondo  1 , Carmen de Mendoza  1 , Miguel Yebra  1 , Juan-Antonio Vargas  1
Affiliations

Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry

Víctor Moreno-Torres et al. J Clin Med. .

Abstract

Background: the admission and death causes of SLE patients might have changed over the last years.

Methods: Analysis of the Spanish National Hospital Discharge database. All individuals admitted with SLE, according to ICD-9, were selected. The following five admission categories were considered: SLE, cardiovascular disease (CVD), neoplasm, infection, and venous-thromboembolic disease (VTED), along four periods of time (1997-2000, 2001-2005, 2006-2010, and 2011-2015).

Results: The admissions (99,859) from 43.432 patients with SLE were included. The absolute number of admissions increased from 15,807 in 1997-2000 to 31,977 in 2011-2015. SLE decreased as a cause of admission (from 47.1% to 20.8%, p < 0.001), while other categories increased over the time, as follows: 5% to 8.6% for CVD, 8.2% to 13% for infection, and 1.4% to 5.5% for neoplasm (p < 0.001 for all). The admission mortality rate rose from 2.22% to 3.06% (p < 0.001) and the causes of death evolved in parallel with the admission categories. A significant trend to older age was observed over time in the overall population and deceased patients (p < 0.001).

Conclusions: Better control of SLE over the past two decades has led to a decrease in early admissions, and disease chronification. As a counterpart, CVD, infections, and neoplasm have become the main causes of admissions and mortality.

Keywords: cardiovascular disease; hospital admissions; infections; mortality; neoplasm; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cardiovascular disease admissions and deaths. The figure shows the trends in admissions (A) and deaths (B) for cardiovascular disease. Data are expressed as a percentage of total admissions and deaths for cardiovascular disease (left ordered axis) and for the subgroups that comprise cardiovascular disease (right ordered axis).
Figure 2
Figure 2
Infectious disease admissions and deaths. The figure shows the trends in admissions (A) and deaths (B) because of infection. Data are expressed as a percentage of total admissions and deaths for the overall infections (left ordered axis) and for the subgroups that comprise infectious disease (right ordered axis).
Figure 3
Figure 3
Neoplasm admissions and deaths. The figure shows the trends in admissions (A) and deaths (B) because of neoplasm. Data are expressed as a percentage of total admissions and deaths for the overall neoplasms (left ordered axis) and for the benign, solid organ, hematological and unknown origin neoplasm (ordered axis).
See this image and copyright information in PMC

References

    1. Lisnevskaia L., Murphy G., Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878–1888. doi: 10.1016/S0140-6736(14)60128-8. - DOI - PubMed
    1. Kaul A., Gordon C., Crow M.K., Touma Z., Urowitz M.B., van Vollenhoven R., Ruiz-Irastorza G., Hughes G. Systemic lupus erythematosus. Nat. Rev. Dis. Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39. - DOI - PubMed
    1. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., Mejía J.C., Aydintug A.O., Chwalinska-Sadowska H., de Ramón E., et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1000 patients. Medicine. 2003;82:299–308. doi: 10.1097/01.md.0000091181.93122.55. - DOI - PubMed
    1. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., Urowitz M., Fortin P.R., Petri M., Barr S., et al. Mortality in systemic lupus erythematosus. Arthritis Rheumatol. 2006;54:2550–2557. doi: 10.1002/art.21955. - DOI - PubMed
    1. Yen E.Y., Singh R.R. Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000–2015. Arthritis Rheumatol. 2018;70:1251–1255. doi: 10.1002/art.40512. - DOI - PMC - PubMed

LinkOut - more resources